Vanguard Group Inc Sellas Life Sciences Group, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,839,318 shares of SLS stock, worth $4.37 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,839,318
Previous 2,292,857
23.83%
Holding current value
$4.37 Million
Previous $2.32 Million
32.44%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding SLS
# of Institutions
52Shares Held
14.5MCall Options Held
538KPut Options Held
26.3K-
Anson Funds Management LP Dallas, TX7.58MShares$11.7 Million1.95% of portfolio
-
Geode Capital Management, LLC Boston, MA820KShares$1.26 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA689KShares$1.06 Million0.0% of portfolio
-
Black Rock Inc. New York, NY430KShares$662,7660.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il350KShares$538,2370.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $31.6M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...